// App-Quantinova.ai

: Aberrant expression of clock genes in human gastric neuroendocrine tumors type 1

Researchers

Presenter

  • Angeliki Karapanagioti

Principal Investigators

  • Narjes Nasiri-Ansari

  • Kosmas Daskalakis

  • Erasmia Vlachou

  • Georgios Kyriakopoulos

  • Harpal Randeva

  • Gregory Kaltsas

  • Eva Kassi

Medical Centers

  • National & Kapodistrial University of Athens, Medical School, 2nd Department of Psychiatry, Athens, Greece

  • National and Kapodistrian University of Athens, Medical School, 4nd Department of Internal Medicine, Attikon Hospital, Athens, Greece

  • Örebro University, Department of Surgery, Faculty of Medicine and Health, Sweden

  • NIMITS Medical Institution Military Shareholder Fund, Department of Gastroenterology, Athens, Greece

  • University Hospital Coventry & Warwickshire, Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), Coventry, United Kingdom

  • Warwick Medical School, Division of Translational and Experimental Medicine- Metabolic and Vascular Health, United Kingdom

Locations

  • Greece

  • Sweden

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Neuroendocrine tumors

Biomarkers

  • Aryl hydrocarbon receptor nuclear translocator-like protein 1

  • Peripheral blood mononuclear cell

  • CLOCK

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved